In-person interactions enrich and eventually improve the outcomes that we are able to provide to our trainees, and thus to patients and the field of oncology.
It's a time for reflecting from an academic and educational standpoint in the field of oncology and translational and clinical research. I recently attended 2 meetings, the Society for Immunotherapy of Cancer (SITC) and the 6th Annual International Congress on Immunotherapies in Cancer®: Focus on Practice-Changing Application, sponsored by Physicians’ Education Resource® (PER®).
SITC was held at the Washington, DC, convention center and the PER® meeting was held in New York City. In my view, as an attendee and invited speaker, both meetings were a success. A wonderful series of presentations was accompanied by the usual and enjoyable human interaction between colleagues and friends. The scientific presentations were focused on new cellular therapies and chimeric antigen receptor (CAR) cells using T cells and NK cells. We remembered the giants of immunotherapy, Thomas A. Waldmann, MD, and Martin “Mac” Cheever, MD, who had passed somewhat unexpectedly in the previous months. Crystal L. Mackall, MD, received the Richard V. Smalley Memorial Award and Lectureship.
I point out these details to indicate how important human interaction is to cancer research and treatment. But a whole generation of trainees has been missing someone walking by their poster or listening to their presentation and providing key feedback that they would never get without an in-person meeting.
The PER® immunotherapy meeting was focused on immuno-oncology advances across multiple cancers and was led by Drs Mario Sznol and Charu Aggarwal. I learned a great deal from the faculty and also from the attendees who posed questions from the floor microphones.
A number of attendees participated virtually, and I give great credit to the IT groups of both meeting organizers for the accommodations to expand participation in the hybrid portion of the meetings. However, I believe those attendees who have participated virtually in the past, myself included, are still missing something. What about our colleagues who may think that it is cheaper and easier to stay in Europe or Asia or even on the other side of our vast United States and open up a browser window to hear a single talk, as opposed to seeing an old friend, developing a new collaboration, or networking to advance their own or one of their mentees’ careers?
I really hope that we de-emphasize and, possibly, maintain some hybridformat conferences but offer, perhaps, a discount or some enticement to those who attend in person. These in-person interactions enrich and eventually improve the outcomes that we are able to provide to our trainees, and thus to patients and the field of oncology.
Leon-Ferre Explores Targeting of PIK3CA Alterations in ER+ Breast Cancer
July 24th 2024During a live Community Case Forum event in partnership with the Minnesota Society of Clinical Oncology, Roberto A. Leon-Ferre, MD, discussed drugs targeting PIK3CA alterations in patients with ER+ metastatic breast cancer.
Read More
Roundtable Roundup: Treatment for Metastatic pMMR Endometrial Cancer
July 23rd 2024In separate, live virtual events, Michael J. Birrer, MD, PhD, and Jubilee Brown, MD, surveyed participants on the treatment of a postmenopausal woman with stage IVA endometrial cancer after first-line chemotherapy.
Read More
George Explores Impact of Risk Status With Cabozantinib/Nivolumab in Advanced RCC
July 19th 2024During a Case-Based Roundtable® event, Daniel George, MD, discussed the results of the CheckMate 9ER trial across favorable, intermediate, and poor risk groups in patients with advanced renal cell carcinoma.
Read More
Depth of Response With Quadruplet Regimens Considered in Newly Diagnosed Multiple Myeloma
July 18th 2024During a Case-Based Roundtable® event, Timothy Schmidt, MD, and participants discussed treatment selection for a 54-year-old patient with transplant eligible R-ISS stage 2/R2-ISS stage 3 IgG-κ myeloma.
Read More
Rossetti Reviews Myelofibrosis Risk Stratification and Outcome Data for Pacritinib
July 17th 2024During a Case-Based Roundtable® event, James M. Rossetti, DO, discussed the role of risk scoring and stratification tools and treatment for a patient with declining hemoglobin and platelet counts due to primary myelofibrosis.
Read More